ArticleInternational journal of hepatology2026
Early Radiological Intervention in Budd-Chiari Syndrome: Clinical Outcomes From a Single-Center Study.
Article in International journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Radiological Intervention in Budd-Chiari Syndrome: Clinical Outcomes From a Single-Center Study.International journal of hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Budd-Chiari Syndrome (BCS) is a vascular disease of the liver characterized by venous outflow obstruction most often due to a myeloproliferative neoplasm (MPN). Restoration of hepatic venous outflow and long-term anticoagulation remain the mainstay of treatment. We examined our experiences and treatment outcomes of BCS, including comprehensive testing for underlying MPN. Methods: A retrospective study was conducted to assess overall and transplant-free survival in patients with primary BCS. All cases of primary BCS that presented to our institution over the past 3 decades were included. Details relating to their hematological work-up and radiological interventions were recorded, as well as their longer term outcomes, including the need for liver transplantation. Results: Forty-three primary BCS patients were identified over a 28-year period, with a median follow-up time of 134 months. MPN was detected in 25 (62.5%) of cases who had comprehensive testing. All patients received primary anticoagulation. Seventeen (39.5%) patients underwent primary transjugular intrahepatic portosystemic shunt (TIPS). Twenty (46.5%) received anticoagulation alone as primary therapy, of whom 14 (70%) failed therapy and ultimately needed a rescue TIPS. Four (9.3%) patients underwent liver transplantation. Overall survival was 100% and 92.9% at 1 and 5 years, respectively, with transplant-free survival of 97.7% and 88.1% at 1 and 5 years, respectively. Conclusion: MPN (particularly JAK2V617F-positive) is an important underlying cause of primary BCS. Anticoagulation alone without radiological intervention can lead to disease progression. In this single-center cohort, early TIPS for rapid hepatic decompression appeared safe and was associated with excellent long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.